Proliferation of normal and malignant prostate epithelium is regulated by androgen stimulation via both the androgen receptor (AR)-positive stromal and epithelial cells. However, it is not known how AR expression is regulated in human prostate cells. We report that treatment of normal human prostate stromal cells (PrSCs) with type I IFN (alpha or beta), but not type II IFN (gamma), resulted in increased levels of AR protein. The maximal increase in AR protein levels was dependent on the dose and the duration of the IFN-alpha treatment. We found that the increase in AR protein levels was independent of de novo transcription and protein synthesis. Interestingly, the IFN-alpha treatment of PrSCs resulted in considerable nuclear accumulation of AR, stimulation of AR-mediated transcription of reporter genes, and retardation of cell proliferation. Furthermore, treatment of normal human prostate epithelial cells with IFNs (alpha, beta or gamma) also resulted in increased levels of AR protein. Together, our observations identify the androgen receptor as an IFN-regulated protein in normal human prostate stromal and epithelial cells and predict that IFN-induced levels of AR in prostate cells contribute to the regulation of androgen signaling.
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Functional interactions between prostate stromal and epithelial cells are important for normal growth and development of the prostate gland (Condon and Bosland, 1999; Arnold and Isaacs, 2002) . Moreover, proliferation of normal and malignant prostate epithelium is regulated by androgen stimulation via both the androgen receptor (AR)-positive stromal and epithelial cells (Condon and Bosland, 1999; Arnold and Isaacs, 2002) . Importantly, malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma (Olapade-Olaopa et al., 1999) . Furthermore, increased levels of epithelial AR and decreased levels of stromal AR are associated with earlier recurrence of prostate cancer and worse pathological stage after radical prostatectomy in patients with localized prostate cancer (Henshall et al., 2001; Ricciardelli et al., 2005) . These observations provide support for the idea that stromal-epithelial interactions involving androgen signaling through AR may be important in the development and progression of the prostate cancer.
AR, a member of the nuclear receptor superfamily that functions as a ligand-dependent nuclear transcription factor, can activate the growth stimulatory as well as the growth inhibitory pathways in prostate epithelial cells (PrECs) Shen, 2000, 2002) . Expression of AR in normal human PrECs is associated with differentiation of cells, suggesting that alterations in the genetics or environment of the PrECs occur to convert the response of such cells to AR signaling from differentiation to transformation Shen, 2000, 2002) . Notably, regulation of AR activity can be achieved in several different ways: modulation of AR gene expression, androgen binding to AR, AR nuclear translocation, AR protein stability, and AR transactivation (Heinlein and Chang, 2004) . Although, prostate stromal cells (PrSCs) (Janssen et al., 2000) and epithelial (Garraway et al., 2003) cells in culture are known to express low levels of AR, it remains unknown what factors regulate the expression of AR in these cells.
Interferons (IFNs) are a family of cytokines with multiple biological functions, including inhibition of cell growth, regulation of differentiation, and modulation of the immune system (Stark et al., 1998) . The family includes two types of IFNs: type I (alpha and beta) and type II (gamma) (Stark et al., 1998) . Both types of IFNs function through transcriptional activation of IFNactivatable genes encoding the IFN-inducible proteins that mediate the biological activities of IFNs. Importantly, treatment of human prostate cancer cell lines with the type I IFN (Sica et al., 1994) or the type II IFN (Kominsky et al., 2000) is known to inhibit cell growth. Additionally, treatment of human prostate cancer cell line PC-3 with natural IFN-beta is known to upregulate the AR protein levels (Sica et al., 1994) . Notably, expression of a set of IFN-activatable genes is upregulated during the onset of cellular senescence in human PrECs (Untergasser et al., 2002) . Additionally, downregulation of the expression of IFN-inducible proteins in PrECs is associated with the development and progression of prostate cancer (Shou et al., 2002) . Although, these observations implicate a role for IFN-inducible proteins in the regulation of prostate epithelial cell growth, the particular IFN-inducible effector proteins remain to be identified.
Recent studies have suggested a link between infection and/or inflammation in prostate gland and pathogenesis of prostate cancer (Nelson et al., 2003 (Nelson et al., , 2004 . Cytokines, such as IFNs, are produced by cells in response to infection/inflammation in tissues or organs (Malmgaard, 2004; Smyth et al., 2004) , we tested whether IFNs could regulate the expression of AR in normal prostate cells, which are known to express AR protein (Janssen et al., 2000; Garraway et al., 2003) . For this purpose, we chose to test PrSCs. PrSCs were derived from normal prostate tissues of healthy donors. Moreover, these cells stained positive for the expression of vimentin and negative for pan cytokeratin, the characteristic of the normal human PrSCs (Janssen et al., 2000) . PrSCs in culture (passage 3) were treated with IFN-alpha (1000 U/ml), -beta (500 U/ml), or -gamma (10 ng/ml) for 24 h and levels of AR protein were compared by immunoblotting. As shown in Figure 1a (left panel), PrSCs expressed low, but detectable, levels of AR protein. However, treatment of cells with IFN-alpha or beta, but not gamma, resulted in Bthreefold increase in AR protein levels. Moreover, treatment of PrSCs with dihydrotestosterone (DHT), a natural potent ligand for AR (Roy and Chatterjee, 1995) , at the physiological concentration range (1-10 nM) for 24 h also resulted in Bthree-fold upregulation of AR protein ( Figure 1a, right panel) . Importantly, the extent of DHT-mediated upregulation of AR protein in PrSCs was comparable with the IFN (alpha or beta)-induced levels of AR protein.
As type I IFN (alpha or beta) treatment of PrSCs resulted in increased levels of AR protein, we sought to determine whether the increase in AR protein levels was dependent on IFN dose and the duration of the treatment. As shown in Figure 1b , a relatively low dose (250 U/ml) of IFN-alpha was sufficient to increase AR protein levels. However, the maximum increase in AR protein levels was evident at a higher dose (1000 U/ml) of the IFN. Furthermore, we noted that treatment of PrSCs with IFN (1000 U/ml) for 6 h was not sufficient to increase AR protein levels ( Figure 1c ) and the maximal increase was evident after 14 h of IFN treatment. Surprisingly, a slight (B30%) decrease in AR protein levels (as compared to 14 h) was detected after 24 h of IFN treatment. These observations indicated that the type I IFN-mediated increases in AR protein levels in PrSCs were dependent on IFN dose and the duration of the treatment.
Studies have indicated that IFN-alpha-mediated transcriptional activation of genes in humans is donorspecific (Schlaak et al., 2002) . Therefore, we compared IFN-alpha-mediated increases in AR protein levels in PrSCs derived from two independent donors at the same passage number. As shown in Figure 1d , basal levels of AR protein were slightly different in PrSCs derived from two donors (compare lane 1 with 3). Importantly, the IFN-alpha treatment of cells resulted in increased levels of AR protein in cells derived from both the donors, indicating that the IFN-mediated increases in AR protein levels in PrSCs were not unique to a donor. and maintained in SCBM basal medium (Cambrex) with supplements and growth factors suggested by the supplier. Subconfluent cultures of cells (at passage 3) were either left untreated (lane 1) or treated with IFN-alpha (1000 U/ml; universal type I IFN-alpha, PBL Biomedical Laboratories, Piscataway, NJ, USA) (lane 2), IFN-beta (500 U/ml; recombinant, Sigma) (lane 3), or IFN-gamma (10 ng/ml; R&D Systems Inc., Minneapolis, MN, USA) (lane 4). At 24 h after the treatment, total-cell lysates were prepared and subjected to immunoblotting using mouse monoclonal antibodies specific to AR (cat #sc-7305; Santa Cruz Biotech) or actin (cat #A5441, Sigma) as described previously (Xin et al., 2003) . Right panel: Cells were cultured (as described in panel a) and either left untreated (lane 1) or treated with DHT (10 nM) (lane 2) for 24 h. Total cell lysates were analysed by immunoblotting as described in panel a. 1 and 2) or a 17-year-old donor (lot #2F0429; derived from normal prostate tissue) (lanes 3 and 4) were either left untreated (lanes 1 and 3) or treated with IFN-alpha (1000 U/ml for 24 h) (lanes 2 and 4). Cell lysates were prepared and analysed by immunoblotting.
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Treatment of AR-positive prostate cancer cells with DHT is known to increase AR protein levels by stabilization of the AR protein (Lee and Chang, 2003) . Therefore, we sought to determine how type-I IFNs increase the AR protein levels in PrSCs. To determine whether IFN-alpha activates the transcription of the AR gene, we compared the steady-state levels of mRNA encoded by the AR gene by RT-PCR between untreated PrSCs and after treatment of cells with IFN-alpha for 8 or 14 h (as 14 h treatment of PrSCs with IFN-alpha resulted in maximum increase in AR protein levels; see Figure 1c ). We found that in two experiments the IFN-alpha treatment of PrSCs did not result in appreciable increases in the steady-state levels of AR mRNA (Figure 2a , compare lane 2 with 4). Moreover, treatment of cells of RWPE-1 cell line, an immortalized prostate epithelial cell line (Bello et al., 1997) , which were transfected with a reporter plasmid in which the transcription of the reporter gene was driven by the 5 0 -regulatory region (B3.5 kb; for a review see Chlenski et al., 2001 ) of the human AR gene, with IFN-alpha did not result in any stimulation of the activity of the reporter (data not shown). These observations raised the possibility that the post-transcriptional mechanisms may contribute to increased levels of AR protein in IFN-treated PrSCs. To test this possibility, we treated cells with actinomycin D, the general inhibitor of cellular transcription, to inhibit transcription and treated cells with IFN-alpha for 14 h. As shown in Figure 2b , treatment of cells with actinomycin D resulted in B50% decrease in the basal levels of AR protein (compare lane 2 with 1). However, pretreatment of cells with the inhibitor did not significantly affect the IFN-alpha induced levels of AR protein (compare lane 4 with 3), indicating that IFN-alpha-mediated increases in AR protein levels were independent of de novo transcription of the AR gene.
Next, we sought to determine whether IFN-mediated increases in AR protein levels were dependent on new protein synthesis. For this purpose, we either treated cells with IFN-alpha for 14 h or left cells untreated (control cells). Subsequently, we treated cells with cycloheximide, the general inhibitor of cellular protein translation, to inhibit protein synthesis. As shown in 2c, treatment of control cells with cycloheximide resulted in increases in basal levels of AR protein (compare lanes 3 and 5 with lane 1), indicating that inhibition of protein synthesis in PrSCs resulted in stabilization of AR protein. Importantly, treatment of cells with IFN-alpha resulted in increases in AR protein levels (compare lane 2 with 1). However, treatment of these cells with the inhibitor did not have any significant effect on IFN-alpha-induced levels of AR protein, suggesting that the IFN-alpha-mediated increases in AR protein levels in PrSCs did not depend on new protein synthesis.
As androgen receptor antagonists are known to function, in part, by destabilizing the AR protein in AR-positive prostate cancer cells (Lee and Chang, 2003; Heinlein and Chang, 2004) , we tested the effect of flutamide, an AR antagonist, on IFN-induced levels of AR protein in PrSCs. As shown in Figure 2d , the presence of flutamide (1 or 2 mM) in culture resulted in B50-70% reduction in the basal levels of AR protein.
However, pretreatment of cells with flutamide did not have any appreciable effect on IFN-alpha-induced levels of AR, indicating that IFN-alpha-mediated increases in AR protein levels in PrSCs were resistant to flutamidemediated destabilization of AR protein. Moreover, we found that treatment of PrSCs with IFN-alpha for 14 h ) were treated with IFN-alpha (1000 U/ml) for the indicated time (h) and total RNA was prepared using TRIzol reagent (Invitrogen). Isolated total RNA (1 mg) was subjected to cDNA synthesis using SuperScript First-Stand Synthesis system (Invitrogen) as suggested by the supplier followed by PCR, using a pair of primer specific to human AR gene ((5 0 -acacattgaaggctat gaatgtc-3 0 ) and (5 0 -tcactgggtgtggaaatagatggg-3 0 )) or actin gene as described previously (Xin et al., 2003) . As a positive control, we also used total RNA from LNCaP prostate cancer cell line (lane 1). (b) Cells (as in panel a) were either left untreated (lane 1) or treated with actinomycin D (10 nM; lane 2), IFN-alpha (1000 U/ml; lane 3), or first with actinomycin D alone (for 2 h) and then with IFN-alpha (lane 4). Cells were lysed after 24 h and the lysates were analysed by immunoblotting using antibodies specific to the indicated proteins. (c) Cells cultured as described in panel a were either left untreated (lanes 1, 3, and 5) or treated with IFN-alpha for 14 h (lanes 2, 4, and 6). Cells were subsequently treated with cycloheximide (25 mg/ ml, Sigma) for either 4 (lanes 3 and 4) or 7 h (lanes 5 and 6) in the presence of IFN. Cells were lysed and the lysates were analysed by immunoblotting using antibodies specific to the indicated proteins. (d) Cells (as in panel a) were either left untreated (lane 1) or treated with flutamide (1 or 2 mM; Sigma) (lanes 3 and 4, respectively), IFN-alpha (1000 U/ml; lane 2), or first with flutamide alone (1 or 2 mM for 14 h; lanes 5 and 6, respectively) and then with IFN-alpha (1000 U/ml). Cells were lysed after 24 h and the lysates were analysed by immunoblotting using antibodies specific to the indicated proteins. (e) Cells (as in panel a) were either left untreated (lane 1) or treated with IFN-alpha (1000 U/ml; lanes 2-5) for 14 h. After 14 h cells were incubated in medium without IFN-alpha for 4 or 7 h (lanes 3 and 4, respectively). Cells were lysed and the lysates were analysed by immunoblotting using antibodies specific to the indicated proteins.
Regulation of androgen receptor levels by interferons Z Basrawala et al (which resulted in increases in AR protein levels), followed by removal of IFN from the culture medium for 4 h, resulted in decreases in AR protein levels to the basal uninduced levels ( Figure 2e ). As the half-life of AR in LNCaP prostate cancer cell line without DHT is estimated to be short (B3 h) (Yeh et al., 1999) , together, our above observations are consistent with the possibility that IFN treatment of PrSCs increases the AR protein levels, in part, by protein stabilization.
To explore the functional consequences of the increased levels of AR protein in PrSCs by IFN-alpha, we first determined whether the IFN treatment has any effect on nuclear localization of AR. As shown in Figure 3 (left panel), basal low levels of AR protein were detectable in the cytoplasm as well as in the nucleus of PrSCs. Consistent with a previous report (Chang et al., 1989) , treatment of cells with DHT resulted in upregulation of AR protein levels and its nuclear localization (middle panel). Interestingly, IFN-alpha treatment of cells for 24 h resulted in increased levels of AR protein and 40-60% accumulation of AR in the nucleus (right panel), indicating that IFN-alpha treatment of PrSCs results in significant nuclear accumulation of AR protein.
IFN treatment of prostate cancer cells is known to inhibit cell proliferation (Sica et al., 1994; Kominsky et al., 2000) . However, it is not known whether IFNtreatment of PrSCs results in inhibition of cell growth. Therefore, we compared changes in cell morphology and cell proliferation between untreated and treated (treated with IFN-alpha; 1000 U/ml) PrSCs over the period of 4 days. In two experiments (cells from a single donor), we found that IFN-alpha treatment of PrSCs did not result in changes in the morphology of cells. Interestingly, we noted that IFN-alpha treatment of cells resulted in B30% reduction in cell number (as compared to untreated cells) in 4 days. Furthermore, cell cycle analysis (by flowcytometry) of control and IFN-alpha (1000 U/ml) treated cells (treated for 24 or 48 h) revealed that cells did not accumulate in a particular phase of the cell cycle. Moreover, we could not detect cells in the sub-G 0 phase, an indicative of cell death or apoptosis. Therefore, a decrease in PrSC number in response to IFN-alpha treatment is consistent with the possibility that IFN-alpha induced levels of AR in these cells are correlated with retardation of cell proliferation (i.e., prolongation of all phases of the cell cycle). The IFN (alpha, beta, or gamma) treatment of a variety of cells is known to result in retardation of cell proliferation (Choubey, 2000) .
Androgen-stimulated nuclear localization of AR in PrECs results in transcriptional activation or repression of target genes (Heinlein and Chang, 2004) . Therefore, substantial nuclear localization of AR in PrSCs after androgen or IFN-alpha treatment prompted us to assess the transcriptional activity of the AR. For this purpose, we nucleofected PrSCs with the AR-responsive reporter plasmids, such as ARE-e1b-luc (AR-luc; Agoulnik et al., 2003) or PSA-luc (Shenk et al., 2001) , and subsequently treated cells with either DHT (10 nM) or IFN-alpha (1000 U/ml). As shown in Figure 4a , treatment of cells with DHT resulted in stimulation of the activity of AR-luc and PSA-luc reporters, indicating that these reporters are responsive to androgen signaling in normal PrSCs. Interestingly, consistent with considerable nuclear localization of AR protein in PrSCs after IFN-alpha treatment (Figure 3) , the treatment of PrSCs with IFN-alpha also resulted in stimulation of the activity of both the reporters albeit to a lesser extent than DHT-treated cells (Figure 4b ). To determine whether IFN-alpha-mediated stimulation of the activity of reporters was depended on the AR expression, we chose to knockdown the expression of AR in PrSCs. As shown in Figure 4c (inset), nucleofection of PrScs with a plasmid (pKD-AR-v1; Upstate, Lake Placid, NY, USA), encoding siRNA to mammalian AR, but not the negative control plasmid, resulted in knockdown of AR protein expression. Importantly, the knockdown of AR expression in PrSCs inhibited the stimulation of the activity of AR-luc reporter by IFN-alpha treatment (Figure 4c ; we used AR-luc reporter because it responded to IFN-alpha treatment better than the PSA-luc-reporter plasmid). Altogether, these observations indicated that IFN-alpha treatment of normal PrSCs stimulated the AR-mediated transcription of reporter genes.
Normal human PrECs in culture are known to express low levels of AR (Garraway et al., 2003) . Moreover, treatment of human prostate cancer cell line PC-3 with natural IFN-beta is known to increase AR protein levels (Sica et al., 1994) . Therefore, we tested Figure 3 Treatment of PrSCs with IFN-alpha results in nuclear localization of AR. Human PrSCs (lot #2F0429) were cultured on glass cover slips in a six-well plate. Cells were either left untreated (left panel), treated with DHT (10 nM; middle panel), or IFN-alpha (1000 U/ml; right panel) for 24 h. Cells were fixed with 100% methanol at room temperature and processed for indirect immunoflourescence microscopy to localize the AR protein, as described previously (Xin et al., 2003) . The secondary anti-mouse IgG-conjugated to rhodamine flourochrome (Sigma, cat #T6528) detected the monoclonal antibodies to AR (sc-7305).
whether IFN (alpha, beta, or gamma) treatment of normal human PrECs results in increases in AR protein levels. As shown in Figure 4d , treatment of normal human PrECs (at passage 4) with IFN-alpha, beta, or gamma, resulted in increases in AR protein levels as compared to control cells (compare lanes 2, 3, and 4 with lane 1). Moreover, at the concentrations of the IFNs tested, the maximum increase in AR protein levels was detected in cells treated with IFN-alpha, raising the possibility that IFNs (alpha, beta, or gamma) may differentially regulate the AR protein levels in normal PrECs.
IFNs (type I and type II) are known to mediate various biological activities by activating the transcription of IFN-activatable genes that encode the IFN-inducible proteins mediating various biological functions of IFNs (Stark et al., 1998) . Therefore, our observation that IFN treatment of PrSCs resulted in increases in AR protein levels by mechanisms independent of transcriptional activation of the AR gene is novel. Consequently, it is not surprising that mRNAbased screens have failed to identify the AR gene as an IFN-activatable gene.
Mechanisms of AR protein degradation are complex (Lee and Chang, 2003) . Studies have suggested that two independent pathways may degrade AR protein: Akt-proteosome and PTEN-caspase-3 pathways (Lee and Chang, 2003) . As IFN-regulated proteins are known to modulate protein degradation by proteosome pathway (Caraglia et al., 2005) , further work will be needed to determine how IFNs decrease degradation of AR protein in PrCSs.
Reexpression of AR in prostate cancer cell lines, which do not express AR (or express low levels of AR), results in inhibition of cell growth (Heinlein and Chang, 2004) . Additionally, studies have provided support for the idea that, within nonmalignant PrECs, the ligandoccupied AR functions as a growth suppressor through its ability to inhibit andromedin-induced proliferation of PrECs to induce differentiation (Litvinov et al., 2004) . Consistent with this growth inhibitory role of AR, we found that IFN-treatment of PrSCs, which resulted in increases in AR protein levels, was associated with retardation of cell proliferation. Therefore, our observations are consistent with the possibility that IFNinduced levels of AR in PrSCs and PrECs contribute to retardation of cell growth.
Treatment of normal PrSCs and PrECs with IFNs resulted in increases in AR protein levels. Furthermore, treatment of PrSCs with IFN-alpha also resulted in considerable nuclear localization of AR protein and stimulation of the activity of AR-responsive reporter genes. As AR-mediated transcriptional regulation of genes is complex (Heinlein and Chang, 2004) , further work will be needed to determine how IFNs regulate the AR-mediated transcription in normal PrSCs.
In summary, our observations support the idea that androgen receptor is a novel effector of IFN action in prostate stromal and epithelial cells. These observations will help us understand the functional role of AR in androgen signaling, which is important in stromal and epithelial interactions during the development of prostate cancer. Figure 1a) were nucleofected with either ARE-e1b-luc (Agoulnik et al., 2003) or PSA-luc (Shenk et al, 2001) reporter plasmid along with pRL-TK reporter plasmid (in 5:1 ratio; total plasmid DNA 2 mg) using Nucleofector-II device (Amaxa Biosystems, Germany; Nucleofection Kit VPD-1004 and program P-022). At 6 h after nucleofection of cells, they were treated with either DHT (10 nM) (panel a) or IFN-alpha (1000 U/ml) (panel b). At 24 h after nucleofections, cells were processed for dual luciferase activity as described previously (Xin et al., 2004) . The normalized relative luciferase activity is shown. We note that IFN-alpha treatment of cells did not result in decreases in the activity of Renilla luciferase. (c) PrSCs (same as in panel a) were nucleofected (as described in panel a above) with either negative control plasmid (columns 1 and 3) or the plasmid (pKD-AR-v1; Upstate, Lake Placid, NY, USA) encoding siRNA for mammalian AR (plasmid DNA, 1.0 mg) (columns 2 and 4) along with the ARE-e1b-luc (0.8 mg) and pRL-TK (0.2 mg) reporter plasmids. At 24 h after nucleofections, cells were either left untreated (columns 1 and 2) or treated with IFN-alpha. At 46 h after nucleofections, cells were processed for dual luciferase activity as described above. Cell lysates that were used for reporter assays (columns 1 and 2) were also analysed by immunoblotting for knockdown of AR protein expression using antibodies specific to AR or actin protein (see inset). (d) PrECs (lot #3F0854, derived from normal prostate tissue of 19-year-old donor) were purchased from Cambrex (Wallkersville, MD, USA) and maintained in PrEBM basal medium (Cambrex) with supplements and growth factors suggested by the supplier. Subconfluent cultures of cells (at passage 4) were either left untreated (lane 1) or treated with IFN-alpha (1000 U/ml) (lane 2), IFN-beta (500 U/ml) (lane 3), or IFN-gamma (20 ng/ml) (lane 4). At 24 h after the treatment, total cell lysates were prepared and subjected to immunoblotting using antibodies specific to AR or tubulin protein.
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